- Home
- PAVM vs ALGS Comparison
PAVM vs ALGS Comparison
Compare PAVM & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVM | ALGS |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.1M | 34.6M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PAVM | ALGS |
|---|---|---|
| Price | $1.47 | $2.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $36.50 | ★ $36.88 |
| AVG Volume (30 Days) | 10.3K | ★ 55.4K |
| Earning Date | 11-13-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,000,000.00 | $2,186,000.00 |
| Revenue This Year | $132.39 | $1,433.30 |
| Revenue Next Year | $263.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.00 | N/A |
| 52 Week Low | $0.21 | $2.02 |
| 52 Week High | $43.99 | $13.69 |
Technical Indicators
Market Signals| Indicator | PAVM | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 26.88 | 18.95 |
| Support Level | N/A | N/A |
| Resistance Level | $6.56 | $7.79 |
| Average True Range (ATR) | 0.22 | 0.54 |
| MACD | 0.03 | -0.25 |
| Stochastic Oscillator | 39.82 | 4.17 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.